Plain-English translation of NCT07595770 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding adebrelimab, an immune-boosting medication, to standard chemotherapy and radiation therapy can help treat esophageal squamous cell carcinoma (a specific type of esophageal cancer) more effectively. Currently, even with chemotherapy and radiation, more than half of patients don't get the best possible results. Researchers hope that combining this medication with existing treatments will help more patients achieve complete cancer elimination before surgery.
Current chemotherapy and radiation treatments work for some patients, but many people still experience cancer recurrence after surgery, limiting long-term survival. This study aims to determine whether adding the new immune therapy to standard treatment can significantly improve cure rates and help patients live longer without their cancer coming back.
You likely qualify if…
You likely don't qualify if…
You would receive the new immune medication, chemotherapy drugs, and radiation therapy over several weeks as part of your pre-surgical treatment. Specifically, you would receive two cycles of the medication and chemotherapy drugs (each cycle lasting 3 weeks), followed by a week of radiation therapy (12 doses), with another dose of the immune medication afterward. Between 4 and 6 weeks after completing this therapy, you would undergo surgery to remove the affected part of your esophagus. Throughout this time, you would have regular clinic visits for monitoring and blood tests to ensure the treatment is working and that you are tolerating it well.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China